Compare Amazon.com Inc (AMZN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Novartis AG — how do they compare? Amazon.com Inc trades at $270.61 (market cap $2.94T), while Novartis AG trades at $152.99 (market cap $295.37B). The key difference: Amazon.com Inc is far larger — about 10× Novartis AG's market cap, and Novartis AG pays a 3.07% dividend while Amazon.com Inc pays none. Which is the better fit depends on your goals.
| AMZN | NVS | |
|---|---|---|
Market Cap | $2.94T | $295.37B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $168.62 |
52-Week Low | $198.79 | $119.31 |
Enterprise Value | $3.04T | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $278.09, up 1.32% with strong bullish momentum as technical indicators show the stock above key support levels. The company demonstrates robust fundamentals with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion, representing a 10.83% margin. Recent earnings beats in Q1 and Q2 2026 exceeded expectations significantly, while analyst sentiment remains overwhelmingly positive with 89% buy ratings.
Amazon's outlook remains favorable with continued revenue growth projected to $775.7 billion in 2026 and expanding profit margins. The primary investment opportunity lies in AWS growth and AI chip development, though risks include intense competition in e-commerce and significant capital expenditures. With a consensus price target of $333.86 representing 20% upside potential, the stock appears positioned for continued growth despite near-term overbought technical conditions.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
